

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

ODACTRA
(house dust mite allergen extract)

Status: CVS Caremark Criteria

Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Odactra is an allergen extract indicated as immunotherapy for house dust mite (HDM) induced allergic rhinitis, with or without conjunctivitis, confirmed by *in vitro* testing for IgE antibodies to *Dermatophagoides farinae* or *Dermatophagoides pteronyssinus* house dust mites, or skin testing to licensed house dust mite allergen extracts. Odactra is approved for use in adults 18 through 65 years of age.

Odactra is not indicated for the immediate relief of allergic symptoms

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed as immunotherapy for house dust mite induced allergic rhinitis

AND

- The diagnosis has been confirmed by *in vitro* testing for pollen-specific IgE antibodies for *Dermatophagoides farinae* or *Dermatophagoides pteronyssinus* house dust mites, or skin testing to licensed house dust mite allergen extracts

AND

- The patient does not have any of the following: A) Severe, unstable or uncontrolled asthma, B) History of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy, C) History of eosinophilic esophagitis

AND

- The requested drug is being prescribed by, or in consultation with, an allergist or immunologist

REFERENCES

1. Odactra [package insert]. Hørsholm, Denmark: ALK-Abelló A/S; August 2019.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed February 9, 2021.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed February 9, 2021.